BMS sells HIV medicines to Viiv HealthCare and with them fostemsavir and BMS 955176

BMS has announced that it has entered into two individual agreements with ViiV Healthcare, a global HIV company, to divest its pipeline of investigational HIV medicines consisting of a number of programs at different stages of discovery, preclinical and clinical development. Under these agreements, ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and pre-clinical programs. Once products are approved and commercialized, ViiV Healthcare will pay tiered royalties. The transaction includes fostemsavir (BMS 663068) which is in Phase III trials and is a Breakthrough Therapy and BMS 955176 which is in Phase IIb trials but it does not include HIV drugs from BMS that are already on the market.